Novo Nordisk Sees Earnings Estimates Rise Amid -6.2% Share Price Decline

Novo Nordisk's stock has returned -6.2% over the past month, compared to the Zacks S&P 500 composite's -0.8% change and the Large Cap Pharmaceuticals industry's -2.5% loss. The drugmaker's earnings estimates for Q4 and FY22 have been revised up by 0.3% and 1.1%, respectively, while the next fiscal year's consensus earnings estimate is $3.42, a decrease of -12.9% from the prior year.